RNAi Drugs for Oncology and Ocular Disorders Represent a Promising Area in Future

Monday 15 October 2012, Amsterdam

A new research report by RNCOS entitled, "Global RNAi Market Analysis", says that the global RNAi market is showing promising growth and robust research activities in future. There are several RNAi drugs in the pipeline and RNAi drugs focused for cancer and ocular and retinal diseases. RNAi drugs have multiple applications in cancer that help in preventing multiple oncogenic gene fusion and suppression of tumor development and also aid in preventing the spread of the tumor. siRNA-based drugs for ocular diseases are growing due to the easier accessibility to the eye and additionally high specificity.

Several industries are rapidly employing RNAi technologies and applications have grown in widespread areas, such as functional genomics, disease diagnostics, agriculture etc. The competitive front represents a wide array of players in RNAi research, such as Alnylam, Isis, Tekmira etc., and RNAi business solutions providers including Bioneer Corporation, Dharmacon, Integrated DNA Technologies and Life Technologies etc. According to the latest report by RNCOS, "Global RNAi Market Analysis", the global RNAi industry is set to grow at a CAGR of around 16% from 2011 to 2015.

The report spread in over 100 pages provides a clear understanding of the RNAi market globally and its current state. Recent industry activities in key geographies, such as US, Europe and Asia Pacific have been covered in the report. RNAi applications in broad areas, such as Therapeutics, Drug Discovery & Development and Agriculture have been discussed. Products and services of key market players have also been listed. The therapeutic market is expected to evolve greatly in future and the report covers a detailed analysis on the therapeutics in the development pipeline. An analysis of the key market trends and key competitor analysis provides a holistic understanding to the reader on the industry's current state.